Ovarian cancers : advances through international research cooperation (GINECO, ENGOT, GCIG)

This book provides an overview of the latest developments in the concepts and management of ovarian cancer. The new data presented throughout opens the way to radically different therapeutic approaches. Surgery remains the core of ovarian cancer treatment, but its ultimate goal and the standard surgical procedure have evolved, giving rise to the question of how to label expert centers for debulking surgery. Neo-adjuvant chemotherapy is becoming more popular and is also a new field for testing novel drug combinations. Over recent years, ovarian cancer management has embraced molecular biology. It is now more correct to talk about cancers of the ovary rather than ovarian cancer, since it is not a unique disease but several entities with different molecular drivers. The significant advances in drugs targeting the microenvironment or the tumor cell DNA repair mechanisms are presented in detail together with exciting future perspectives. All these advances would not have been possible without collaborative groups such as the GINECO group in France and their integration in wider clinical research networks at the European (ENGOT) and international (GCIG) level. Front Matter....Pages i-x Front Matter....Pages 1-1 Clinical Research in France, Europe, and in the World Dedicated to Ovarian Cancers....Pages 3-12 Genetics of Ovarian Carcinomas....Pages 13-31 Debulking Surgery: Interval Debulking Surgery Versus Primary: Pros and Cons on How to Evaluate Quality....Pages 33-42 How to Evaluate Tumor Burden Before Therapeutic Decision....Pages 43-58 Value of Lymphadenectomy....Pages 59-65 Ovarian Cancer and HIPEC: In the Era of Evidence Based Medicine....Pages 67-78 Oncofertility Applied to Epithelial Ovarian Cancer....Pages 79-94 First-Line Systemic Therapy (Chemo/Antiangiogenics)....Pages 95-112 Ovarian Cancer in the Elderly....Pages 113-132 Treatment at Relapse (Surgery and Systemic Treatments)....Pages 133-142 The Future in Ovarian Cancer: Advances in Immunotherapies....Pages 143-168 Front Matter....Pages 169-169 High-Grade Carcinomas, BRCA Mutations and the Role of PARP Inhibitors....Pages 171-182 Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary or Peritoneum....Pages 183-200 Clear Cell Carcinoma....Pages 201-209 Endometrioid Carcinoma of the Ovary....Pages 211-220 Mucinous Carcinoma of the Ovary....Pages 221-232 Gynecological Carcinosarcomas....Pages 233-246 Malignant Ovarian Germ Cell Tumours: An Overview of Management and Controversies....Pages 247-259 Ovarian Sex Cord Tumors....Pages 261-279 Small Cell Carcinoma of the Ovary....Pages 281-286